**I/We claim:**

1. Use of a cannabinoid composition in the manufacture of a medicament for the treatment of a neurodegenerative disease, wherein the cannabinoid composition comprises: cannabidiol and cannabigerol, wherein a mass ratio of the cannabidiol to the cannabigerol is from 1:1 to 1:10 and is not 1:1.

2. The use according to claim 1, wherein the mass ratio of the cannabidiol to the cannabigerol is from 1:1 to 1:3, or from 1:3 to 1:5, or from 1:5 to 1:7.

3. The use according to claim 1, wherein the mass ratio of the cannabidiol to the cannabigerol is 1:3.

4. The use according to any one of claims 1 to 3, wherein the cannabinoid composition further comprises cannabinol.

5. The use according to claim 4, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.05 to 1:1.

6. The use according to claim 4, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.1 to 1:0.5.

7. The use according to claim 4, wherein a mass ratio between the cannabidiol, the cannabigerol, and cannabinol is 1:3:0.3.

8. The use according to any one of claims 1 to 7, wherein the medicament is in a dosage form selected from the group consisting of: oil agent, granule, tablet, pulvis, capsule, pill, powder, oral liquid, gel, spray, and aerosol.

9. The use according to any one of claims 1 to 8, wherein the neurodegenerative disease is selected from the group consisting of: Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies.

10. A cannabinoid composition, comprising: cannabidiol and cannabigerol, wherein a mass ratio of the cannabidiol to the cannabigerol is 1:3.

11. The cannabinoid composition according to claim 10, wherein the cannabinoid composition further comprises cannabinol.

12. The cannabinoid composition according to claim 11, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.05 to 1:1.

13. The cannabinoid composition according to claim 11, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.1 to 1:0.5.

14. The cannabinoid composition according to claim 11, wherein a mass ratio between the cannabidiol, the cannabigerol, and cannabinol is 1:3:0.3.